Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.…
Voting Rights and Shares Capital of the Company
Nanobiotix (NASDAQ: NBTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 98 employees.
The shares were at 26.50 USD on 20 November 2026, up 22.8% over 52 weeks. Its 52-week range is 19.14 USD to 57.14 USD: the price is 53.6% below the high and 38.5% above the low.
Its market capitalisation is 1.35B USD.
Nanobiotix reports return on equity of 28.4%, an operating margin of -257.4% and revenue down 79.2% year over year.
It holds more cash than debt, a net cash position of 4.28M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 53.31 USD is 101.2% above the current price. The next earnings report is expected on 30 March 2027.